Formulation and in Vitro Evaluation of Granisetron and Cabazitaxel Bilayered Tablets

In the present study, the bilayered tablets were effectively formulated using Granisetron as immediate release layer and Cabazitaxel as controlled release layer by using direct compression method. Granisetron, an antagonist of the serotonin 5-HT3 receptor, is used as an antiemetic, while Cabazitaxel, an anticancer drug, is used to treat metastatic prostate cancer. Six Formulations of Granisetron and Cabazitaxel were prepared and evaluated for various physicochemical parameters such as hardness, friability and drug content. The optimized formulation GR-6 in immediate release layer formulation exhibited the average hardness of 4.3 kg/cm2 , friability of 0.40% and drug content 100.8%. The CB-6 as controlled release layer in formulation exhibited an average hardness of 3.4 kg/cm2 , friability of 0.42% and drug content 99.6% was determined. Both Granisetron and Cabazitaxel optimized layers were prepared as bilayered tablets by using polymers such as Ethyl cellulose, Eudragit, Guar gum, Hydroxypropyl cellulose and starch glycolate sodium. Cabazitaxel was released in a controlled manner in the first hour, while the remaining drug was released for up to 12 hours, and the Granisetron formulation showed 100.4% drug release.